The realisation of targeted antitumour therapy

British Journal of Cancer

Volumn 92, Issue , 2005, Pages S2-S5

  Bicknell, R ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Angiogenesis; Antitumour; EGF; Targeted therapy; VEGF

Indexed keywords

ACETYLCYSTEINE; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IMATINIB; INTERLEUKIN 8; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; TRASTUZUMAB; VANDETANIB; VASCULOTROPIN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; DRUG TARGETING; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GROWTH INHIBITION; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MALIGNANT TRANSFORMATION; NONHODGKIN LYMPHOMA; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CELL SURVIVAL; ENZYME INHIBITORS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN-TYROSINE KINASES;

EID: 21244490748     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602602     Document Type: Article

References (20)

1. Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3: 401-410
2. Brown NS, Streeter EH, Jones A, Harris AL, Bicknell R (2005) Cooperative stimulation of vascular endothelial growth factor expression by hypoxia and reactive oxygen species: the effect of targeting vascular endothelial growth factor and oxidative stress in an orthotopic xenograft model of bladder carcinoma. Br J Cancer 19 April 2005 [Epub ahead of print]. doi: 10.1038/sj.bjc.6602522 www.bjcancer.com
3. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407: 249-257
4. Drevs J, Medinger M, Schmidt-Gersbach C, Weber R, Unger C (2003) Receptor tyrosine kinases: the main targets for new anticancer therapy. Curr Drug Targets 4: 113-121
5. Ellis LM (2004) Preclinical data targeting vascular endothelial growth factor in colorectal cancer. Clin Colorectal Cancer 4(Suppl 2): S55-S61
6. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9: 669-676
7. Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3: 391-400
8. Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4-6
9. Green MR (2004) Targeting targeted therapy. N Engl J Med 350: 2191-2193
10. Harris M (2004) Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol 5: 292-302
11. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342
12. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58-62
13. Kerbel R, Folkman J (2002) Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2: 727-739
14. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362: 841-844
15. Marjon PL, Bobrovnikova-Marjon EV, Abcouwer SF (2004) Expression of the pro-angiogenic factors vascular endothelial growth factor and interleukin-8/CXCL8 by human breast carcinomas is responsive to nutrient deprivation and endoplasmic reticulum stress. Mol Cancer 3: 4
16. Miller JC, Pien HH, Sahani D, Sorensen AG, Thrall JH (2005) Imaging angiogenesis: applications and potential for drug development. J Natl Cancer Inst 97: 172-187
17. Neri D, Bicknell R (2005) Tumour vascular targeting. Nat Rev Cancer in press
18. Shweiki D, Itin A, Soffer D, Keshet E (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359: 843-845
19. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrove HL, Graham GA, Hughes GD, Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF, Bigley AL, Hennequin LF (2002) ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62: 4645-4655
20. Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O'Reilly T, Persohn E, Rosel J, Schnell C, Stover D, Theuer A, Towbin H, Wenger F, Woods-Cook K, Menrad A, Siemeister G, Schirner M, Thierauch KH, Schneider MR, Drevs J, Martiny-Baron G, Totzke F (2000) PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60: 2178-2189